「小普日报」2023年11月10日热点速递
关键词 奥希替尼 纳武利尤单抗 肉毒毒素 循环肿瘤 DNA测序 维布妥昔单抗 依库珠单抗 呋喹替尼 非酒精性脂肪性肝炎
#今日行业热点#
①The New England Journal of Medicine：Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC 临床试验：第三代表皮生长因子受体酪氨酸激酶抑制剂奥希替尼单药或联合化疗用于EGFR突变晚期非小细胞肺癌（NSCLC） DOI: 10.1056/NEJMoa2306434
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC | NEJM
②The New England Journal of Medicine：Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma 临床试验：纳武利尤单抗（Nivolumab）联合铂类药物用于晚期尿路上皮癌的Ⅲ期、多国、开放标签试验 DOI: 10.1056/NEJMoa2309863
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma | NEJM
③The New England Journal of Medicine：Trial of Botulinum Toxin for Isolated or Essential Head Tremor 临床试验：肉毒毒素用于孤立性或原发性头部震颤的试验：一项多中心、双盲、随机试验 DOI: 10.1056/NEJMoa2304192
Trial of Botulinum Toxin for Isolated or Essential Head Tremor | NEJM
④Blood：Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA 研究：超敏感的循环肿瘤(CT)DNA测序在中枢神经系统淋巴瘤(CNSL)的作用 DOI: 10.1182/blood.2023022020
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA | Blood | American Society of Hematology (ashpublications.org)
⑤Blood：Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy 临床数据：抗体偶联药物（ADC）维布妥昔单抗(Brentuximab vedotin)联合达卡巴嗪或纳武利尤单抗用于老年经典型霍奇金淋巴瘤（cHL） DOI: 10.1182/blood.2022019536
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy | Blood | American Society of Hematology (ashpublications.org)
⑥Blood：Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA 依库珠单抗（Eculizumab）用于高危干细胞移植相关血栓性微血管病（TMA）的前瞻性多机构研究 DOI: 10.1182/blood.2023022526
Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA | Blood | American Society of Hematology (ashpublications.org)
⑦VEGFR抑制剂呋喹替尼获FDA批准上市，用于既往使用过氟嘧啶、奥沙利铂和伊立替康的转移性结直肠癌 ⑧靶向CD47的SIRPαFc融合蛋白IMM01获FDA授予孤儿药资格，联合阿扎胞甘用于慢性粒单核细胞白血病（CMML） ⑨CDK4选择性抑制剂BGB-43395注册一项Ⅰ期临床试验，拟评估单药或联合氟维司群或来曲唑用于HR+/HER 2-乳腺癌（BC）和其他晚期实体瘤 ⑩甲状腺激素β受体（THR-β）选择性激动剂KH629获FDA批准开展新药研究，拟开发用于非酒精性脂肪性肝炎（NASH） 科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！
